Advancements of Emerging Thiazole‐Based CDKs Inhibitors for Cancer Therapy: From Hits to Clinical Candidates
Drug Development Research · 2026-11 · 87 (7)
DOI: 10.1002/ddr.70398 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, online erschienen am 22.10.2026. Verfasst von Menglin Luo und 3 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, PR China. Hauptthemen laut MEDLINE: Thiazoles, Antineoplastic Agents, Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 81 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National College Students Innovation and Entrepreneurship Training Program.
Abstract (Originalsprache)
Cyclin‐dependent kinases (CDKs) represent highly attractive anticancer targets and several inhibitors have been approved for cancer therapy. However, drug resistance and dose‐dependent toxicity have limited clinical application. Therefore, discovering new CDKs inhibitors featuring novel scaffolds and high selectivity for disease treatment and target research remains to attract significant interest from both academics and industry. Recently, thiazole has emerged as a privileged heterocyclic scaffold for design and synthesis of antitumor drugs targeting CDKs. Currently, although there are no FDA‐approved thiazole‐based CDKs inhibitors, this review systematically summarizes the evolution of inhibitors from early hits to clinical‐stage candidates including GFH009, SNS‐032, and JSH‐150, with particular emphasis on structure‐based drug design strategies. Furthermore, we highlight the challenges and future prospects in development of thiazole derivatives targeting CDKs, with particular emphasis on discovery of next‐generation, highly selective inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou, PR China.
ORCID-Profile: Peiliang Zhao
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National College Students Innovation and Entrepreneurship Training Program
Zitieren
APA
Luo, M., Jiang, S., Ma, Y., & Zhao, P. (2026). Advancements of Emerging Thiazole‐Based CDKs Inhibitors for Cancer Therapy: From Hits to Clinical Candidates. Drug Development Research, 87(7). https://doi.org/10.1002/ddr.70398
Vancouver
Luo M, Jiang S, Ma Y, Zhao P. Advancements of Emerging Thiazole‐Based CDKs Inhibitors for Cancer Therapy: From Hits to Clinical Candidates. Drug Development Research. 2026;87(7). doi:10.1002/ddr.70398
BibTeX
@article{Luo2026,
author = {Luo, Menglin and Jiang, Shuwang and Ma, Yufeng and Zhao, Peiliang},
title = {Advancements of Emerging Thiazole‐Based CDKs Inhibitors for Cancer Therapy: From Hits to Clinical Candidates},
journal = {Drug Development Research},
year = {2026},
volume = {87},
number = {7},
doi = {10.1002/ddr.70398}
}
EUVIMED